Qiu F, Chen S, Li Y, Wang X, Zhu M
PLoS One. 2025; 20(1):e0315811.
PMID: 39752452
PMC: 11698415.
DOI: 10.1371/journal.pone.0315811.
Esplugues F, Andujar I, Esplugues J
Front Pharmacol. 2024; 15:1447324.
PMID: 39364047
PMC: 11446848.
DOI: 10.3389/fphar.2024.1447324.
Fan Y, Xu Q, Jin G, Jiang L, Wang C
Front Public Health. 2024; 12:1383308.
PMID: 39040867
PMC: 11260701.
DOI: 10.3389/fpubh.2024.1383308.
Li J, Zhang X, Wang R, Cao K, Wan L, Ren X
Front Public Health. 2024; 12:1402581.
PMID: 39011324
PMC: 11247172.
DOI: 10.3389/fpubh.2024.1402581.
Wang J, Zhang S, Wang C, Li J, Wang R, Zhu L
BMC Health Serv Res. 2024; 24(1):771.
PMID: 38951849
PMC: 11218069.
DOI: 10.1186/s12913-024-11217-3.
Effect of China national centralized drug procurement policy on anticoagulation selection and hemorrhage events in patients with AF in Suining.
Zhang Q, Wang R, Chen L, Chen W
Front Pharmacol. 2024; 15:1365142.
PMID: 38444941
PMC: 10912648.
DOI: 10.3389/fphar.2024.1365142.
The impact of centralized coronary stent procurement program on acute myocardial infarction treatments: evidence from China.
Jian W, Zhou W, Zhang L
Front Public Health. 2023; 11:1285558.
PMID: 38098831
PMC: 10720903.
DOI: 10.3389/fpubh.2023.1285558.
A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.
Nemeth G, Mago M, Kalo Z, Lam J, Balogh T, Brodszky V
Front Med (Lausanne). 2023; 10:1282698.
PMID: 37964880
PMC: 10642851.
DOI: 10.3389/fmed.2023.1282698.
New pricing models for generic medicines to ensure long-term sustainable competition in Europe.
Francois C, Gawlik G, Mestre-Ferrandiz J, Pana A, Perelman J, Yfantopoulos J
Front Pharmacol. 2023; 14:1200641.
PMID: 37876734
PMC: 10593415.
DOI: 10.3389/fphar.2023.1200641.
Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010-2019).
Brkic A, Diamantopoulos A, Hoff M, Haavardsholm E, Fevang B, Brekke L
BMC Health Serv Res. 2023; 23(1):968.
PMID: 37679747
PMC: 10486045.
DOI: 10.1186/s12913-023-09975-7.
Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
Gu Y, Zhuang Q
Front Pharmacol. 2023; 14:1192423.
PMID: 37324496
PMC: 10266233.
DOI: 10.3389/fphar.2023.1192423.
Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017-2020.
Ehlers L, Jensen M, Schack H
J Pharm Policy Pract. 2022; 15(1):69.
PMID: 36273196
PMC: 9588211.
DOI: 10.1186/s40545-022-00464-6.
Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China.
Xing Q, Tang W, Li M, Li S
Int J Environ Res Public Health. 2022; 19(7).
PMID: 35409966
PMC: 8999037.
DOI: 10.3390/ijerph19074285.
Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China.
Li Z, Liu C, Zuo K, Liu J, Tang Y
Front Pharmacol. 2021; 12:741671.
PMID: 34721029
PMC: 8552023.
DOI: 10.3389/fphar.2021.741671.
Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N, Yang Y, Xu L, Mao Z, Cui D
BMC Public Health. 2021; 21(1):1883.
PMID: 34663282
PMC: 8524972.
DOI: 10.1186/s12889-021-11882-7.
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S, Schneider P, Zuba M, Busse R, Panteli D
Front Pharmacol. 2021; 12:625296.
PMID: 34248615
PMC: 8267415.
DOI: 10.3389/fphar.2021.625296.
Time spent by hospital personnel on drug changes: A time and motion study from an in-and outpatient hospital setting.
Poulsen J, Norgaard L, Dieckmann P, Clemmensen M
PLoS One. 2021; 16(2):e0247499.
PMID: 33630933
PMC: 7906352.
DOI: 10.1371/journal.pone.0247499.
The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China.
Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z
Int J Environ Res Public Health. 2020; 17(24).
PMID: 33334027
PMC: 7765443.
DOI: 10.3390/ijerph17249415.
Tendering and biosimilars: what role for value-added services?.
Simoens S, Cheung R
J Mark Access Health Policy. 2020; 8(1):1705120.
PMID: 32002174
PMC: 6968494.
DOI: 10.1080/20016689.2019.1705120.
Pricing of HPV vaccines in European tender-based settings.
Qendri V, Bogaards J, Berkhof J
Eur J Health Econ. 2018; 20(2):271-280.
PMID: 30051152
PMC: 6439217.
DOI: 10.1007/s10198-018-0996-9.